Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

Lancet (London, England) - 27 Feb 1999

Aithal G P, Day C P, Kesteven P J, Daly A K

Abstract excerpt

BACKGROUND: The cytochrome P450 CYP2C9 is responsible for the metabolism of S-warfarin. Two known allelic variants CYP2C9*2 and CYP2C9*3 differ from the wild type CYP2C9*1 by a single aminoacid substitution in each case. The allelic variants are associated with impaired hydroxylation of S-warfarin in in-vitro expression systems. We have studied the effect of CYP2C9 polymorphism on the in-vivo warfarin dose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Hemorrhage

Share to International Normalized Ratio

Share to Steroid 16-alpha-Hydroxylase

Share to Steroid Hydroxylases

Share to Warfarin

Source

Identifiers

PMID: 10073515
DOI: 10.1016/S0140-6736(98)04474-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.PMID 10073515Read ↗

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.Semantic proximity Read ↗

Cytochrome P450 polymorphisms are associated with reduced warfarin dose.Semantic proximity Read ↗

First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele.Semantic proximity Read ↗

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.Semantic proximity Read ↗

Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis.Semantic proximity Read ↗

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.Semantic proximity Read ↗

Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.Semantic proximity Read ↗

Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients.Semantic proximity Read ↗

Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.Semantic proximity Read ↗

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.Semantic proximity Read ↗

Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.Semantic proximity Read ↗

Warfarin dosing and cytochrome P450 2C9 polymorphisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.